A Strong Business Case for Aesthetic Practices - Sofwave

Robust Corporate and Margin Health: Sofwave achieved a significant milestone in Q2 2025 by reporting its first-ever net income of $1.5 million on $21 million in revenue. The gross margin reported was exceptionally high at 75.5%. The company actively maintains minimum advertised pricing protection to ensure the treatment is viewed as premium, allowing providers to maintain high gross margins on the procedure, making it the "treatment of choice" among multiple options.

High Recurring Revenue: The business model relies on the sale of pulses, which constituted 40% of the company's total revenue in Q2 2025, and recurring revenue grew 53% year-over-year. This demonstrates that patients are consistently returning for treatments, guaranteeing a sustained income stream for the purchasing clinic.

Rapid Throughput and Minimal Downtime: Time efficiency is critical for maximizing a practice’s earning potential. A full-face Sofwave treatment takes about 45 minutes. Since the procedure involves minimal downtime, patients can immediately return to their normal daily activities. This speed is "perfect for busy schedules" and significantly boosts clinic throughput.

Ease of Delegation and Use: The device is described as "exceptionally easy to use and quick to learn

Reliability: The SUPERB™ handpiece utilizes a proprietary solid-state energizer module with no moving parts or optics, contributing to its high durability and reliability.

Precision and Depth: SUPERB™ technology delivers non-focused ultrasound beams, precisely targeting and heating the mid-dermal layer at 1.5 mm to stimulate neocollagenesis and neoelastogenesis.

Epidermal Protection: The device includes Sofcool™ Technology and real-time temperature monitoring, which effectively protects the epidermal layer from thermal damage.

Minimal Pain: The procedure is generally well-tolerated, often requiring only topical anesthesia.

Broad Skin Type Application: The non-invasive ultrasound method is safe for all skin types and tones (including Fitzpatrick types II–IV tested in clinical studies) as it is not affected by melanin, avoiding the risks of hyperpigmentation common with other heat/light-based treatments on darker skin.

Versatile FDA Clearances: Sofwave is FDA-cleared for multiple uses, including lifting the eyebrow, neck, and submental tissue, improving facial lines and wrinkles, improving skin laxity on the upper arms, short-term improvement in cellulite, and treatment of acne scars.

RF Microneedling (RFMN): RFMN involves the use of fine needles and heat delivery beneath the skin. The FDA has issued safety warnings regarding RF microneedling devices due to reports of serious adverse events, including burns, scarring, fat loss, disfigurement, and nerve damage. Practices using RFMN are explicitly advised to review marketing materials and update consent forms to disclose these risks. Sofwave’s entirely non-invasive ultrasound delivery bypasses these risks entirely, as reflected by the reported absence of adverse events in clinical trials.

Fractional Ablative CO2 Lasers (FACL): FACL, while effective, is associated with significant downtime. FACL procedures require extensive pain management, with a consensus among experts favoring topical anesthetic creams, nerve blocks, and oral analgesics. Furthermore, FACL is primarily ideal for patients with fair skin (Fitzpatrick I–II), while Sofwave is safe and effective across a broader range of skin types, including skin of color.

The GLP-1 Phenomenon: The rise of weight loss medications (GLP-1s) is creating a new class of aesthetic patients, with 63% of those seeking aesthetic services being first-time patients. Their primary concern is skin laxity, loose skin, and sagging—a condition often termed "Ozempic face". Sofwave provides the ideal non-surgical lifting solution to address this specific, high-growth demographic.

The Shift to Natural Rejuvenation: The industry is moving away from "overfilled" aesthetics. Dermal filler use decreased by 31% in 2024. In contrast, the market segment demanding skin lifting grew by 39% year-over-year. Sofwave’s mechanism, which stimulates the body’s natural production of collagen and elastin, aligns perfectly with the demand for subtle, natural-looking results and the "Quiet Luxury Face" trend.

Strong Brand Awareness and Demand Generation: Sofwave invests heavily in national branding to drive patient demand directly to its provider partners. The brand achieved a 34% "share of voice" across competitive keywords (like GLP-1 and skin laxity) in Q2 2025, ensuring that when consumers search for solutions, Softwave appears prominently.

Target the New Patient Demographic: Actively market Sofwave’s lifting capabilities to patients experiencing skin laxity following rapid weight loss from GLP-1 medications.

Optimize Staff Utilization: Utilize the device's speed and delegatability to allow trained staff (e.g., nurse practitioners or physician assistants) to manage high-volume Sofwave and Pure Impact VIP™ procedures, maximizing the number of patients treated daily.

Leverage Versatility: Capitalize on the device's numerous FDA clearances, promoting it not just for face/neck lifting, but also for acne scar treatment in patients with diverse skin types, a capability proven safe and effective in clinical studies.

Emphasize Low Risk: Use Sofwave’s excellent safety profile (no downtime, non-invasive, safe for all skin tones) as a key selling point against competitors known for painful procedures (Ultherapy) or serious complications (RF microneedling).